Correlation Between Mid-cap Profund and Pharmaceuticals Ultrasector

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mid-cap Profund and Pharmaceuticals Ultrasector at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mid-cap Profund and Pharmaceuticals Ultrasector into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mid Cap Profund Mid Cap and Pharmaceuticals Ultrasector Profund, you can compare the effects of market volatilities on Mid-cap Profund and Pharmaceuticals Ultrasector and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mid-cap Profund with a short position of Pharmaceuticals Ultrasector. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mid-cap Profund and Pharmaceuticals Ultrasector.

Diversification Opportunities for Mid-cap Profund and Pharmaceuticals Ultrasector

0.18
  Correlation Coefficient

Average diversification

The 3 months correlation between Mid-cap and Pharmaceuticals is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding Mid Cap Profund Mid Cap and Pharmaceuticals Ultrasector Pr in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pharmaceuticals Ultrasector and Mid-cap Profund is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mid Cap Profund Mid Cap are associated (or correlated) with Pharmaceuticals Ultrasector. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pharmaceuticals Ultrasector has no effect on the direction of Mid-cap Profund i.e., Mid-cap Profund and Pharmaceuticals Ultrasector go up and down completely randomly.

Pair Corralation between Mid-cap Profund and Pharmaceuticals Ultrasector

Assuming the 90 days horizon Mid Cap Profund Mid Cap is expected to generate 0.51 times more return on investment than Pharmaceuticals Ultrasector. However, Mid Cap Profund Mid Cap is 1.94 times less risky than Pharmaceuticals Ultrasector. It trades about 0.18 of its potential returns per unit of risk. Pharmaceuticals Ultrasector Profund is currently generating about 0.07 per unit of risk. If you would invest  11,269  in Mid Cap Profund Mid Cap on April 24, 2025 and sell it today you would earn a total of  1,204  from holding Mid Cap Profund Mid Cap or generate 10.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Mid Cap Profund Mid Cap  vs.  Pharmaceuticals Ultrasector Pr

 Performance 
       Timeline  
Mid Cap Profund 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Mid Cap Profund Mid Cap are ranked lower than 14 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak forward indicators, Mid-cap Profund may actually be approaching a critical reversion point that can send shares even higher in August 2025.
Pharmaceuticals Ultrasector 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Pharmaceuticals Ultrasector Profund are ranked lower than 5 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak forward indicators, Pharmaceuticals Ultrasector may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Mid-cap Profund and Pharmaceuticals Ultrasector Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mid-cap Profund and Pharmaceuticals Ultrasector

The main advantage of trading using opposite Mid-cap Profund and Pharmaceuticals Ultrasector positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mid-cap Profund position performs unexpectedly, Pharmaceuticals Ultrasector can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharmaceuticals Ultrasector will offset losses from the drop in Pharmaceuticals Ultrasector's long position.
The idea behind Mid Cap Profund Mid Cap and Pharmaceuticals Ultrasector Profund pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Valuation
Check real value of public entities based on technical and fundamental data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories